315 related articles for article (PubMed ID: 32710713)
1. Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma: A report from the Japanese Pediatric Brain Tumor Consortium.
Okada K; Soejima T; Sakamoto H; Hirato J; Hara J
Pediatr Blood Cancer; 2020 Nov; 67(11):e28572. PubMed ID: 32710713
[TBL] [Abstract][Full Text] [Related]
2. Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: A prospective registry study in Japan.
Yamasaki K; Okada K; Soejima T; Sakamoto H; Hara J
Pediatr Blood Cancer; 2020 Jan; 67(1):e28012. PubMed ID: 31544362
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy after reduced craniospinal irradiation dose in children with average-risk medulloblastoma: a 5-year follow-up study.
Wahba HA; Abu-Hegazy M; Wasel Y; Ismail EI; Zidan AS
J BUON; 2013; 18(2):425-9. PubMed ID: 23818356
[TBL] [Abstract][Full Text] [Related]
4. Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.
Sung KW; Lim DH; Son MH; Lee SH; Yoo KH; Koo HH; Kim JH; Suh YL; Joung YS; Shin HJ
Neuro Oncol; 2013 Mar; 15(3):352-9. PubMed ID: 23258845
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy and overall survival in adult medulloblastoma.
Kann BH; Lester-Coll NH; Park HS; Yeboa DN; Kelly JR; Baehring JM; Becker KP; Yu JB; Bindra RS; Roberts KB
Neuro Oncol; 2017 Feb; 19(2):259-269. PubMed ID: 27540083
[TBL] [Abstract][Full Text] [Related]
6. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
[TBL] [Abstract][Full Text] [Related]
7. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
[TBL] [Abstract][Full Text] [Related]
8. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
[TBL] [Abstract][Full Text] [Related]
9. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients.
Massimino M; Sunyach MP; Barretta F; Gandola L; Garegnani A; Pecori E; Spreafico F; Bonneville-Levard A; Meyronet D; Mottolese C; Boschetti L; Biassoni V; Schiavello E; Giussani C; Carrabba G; Diletto B; Pallotti F; Stefini R; Ferrari A; Terenziani M; Casanova M; Luksch R; Meazza C; Podda M; Chiaravalli S; Puma N; Bergamaschi L; Morosi C; Calareso G; Giangaspero F; Antonelli M; Buttarelli FR; Frappaz D
J Neurooncol; 2020 Jul; 148(3):619-628. PubMed ID: 32567042
[TBL] [Abstract][Full Text] [Related]
10. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Packer RJ; Gajjar A; Vezina G; Rorke-Adams L; Burger PC; Robertson PL; Bayer L; LaFond D; Donahue BR; Marymont MH; Muraszko K; Langston J; Sposto R
J Clin Oncol; 2006 Sep; 24(25):4202-8. PubMed ID: 16943538
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea.
Yoon JH; Park KD; Kang HJ; Kim H; Lee JW; Kim SK; Wang KC; Park SH; Kim IH; Shin HY
World J Pediatr; 2017 Aug; 13(4):367-373. PubMed ID: 28550392
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience.
Atalar B; Ozsahin M; Call J; Napieralska A; Kamer S; Villa S; Erpolat P; Negretti L; Lassen-Ramshad Y; Onal C; Akyurek S; Ugurluer G; Baumert BG; Servagi-Vernat S; Miller RC; Ozyar E; Sio TT
Radiother Oncol; 2018 Apr; 127(1):96-102. PubMed ID: 29373196
[TBL] [Abstract][Full Text] [Related]
13. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.
Lee JW; Lim DH; Sung KW; Cho HW; Ju HY; Hyun JK; Yoo KH; Koo HH; Suh YL; Joung YS; Shin HJ
Cancer Med; 2020 Aug; 9(16):5807-5818. PubMed ID: 32608158
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor.
Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT
Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
Strother D; Ashley D; Kellie SJ; Patel A; Jones-Wallace D; Thompson S; Heideman R; Benaim E; Krance R; Bowman L; Gajjar A
J Clin Oncol; 2001 May; 19(10):2696-704. PubMed ID: 11352962
[TBL] [Abstract][Full Text] [Related]
17. Necrosis after craniospinal irradiation: results from a prospective series of children with central nervous system embryonal tumors.
Murphy ES; Merchant TE; Wu S; Xiong X; Lukose R; Wright KD; Qaddoumi I; Armstrong GT; Broniscer A; Gajjar A
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e655-60. PubMed ID: 22768993
[TBL] [Abstract][Full Text] [Related]
18. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.
von Bueren AO; von Hoff K; Pietsch T; Gerber NU; Warmuth-Metz M; Deinlein F; Zwiener I; Faldum A; Fleischhack G; Benesch M; Krauss J; Kuehl J; Kortmann RD; Rutkowski S
Neuro Oncol; 2011 Jun; 13(6):669-79. PubMed ID: 21636711
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
Gajjar A; Chintagumpala M; Ashley D; Kellie S; Kun LE; Merchant TE; Woo S; Wheeler G; Ahern V; Krasin MJ; Fouladi M; Broniscer A; Krance R; Hale GA; Stewart CF; Dauser R; Sanford RA; Fuller C; Lau C; Boyett JM; Wallace D; Gilbertson RJ
Lancet Oncol; 2006 Oct; 7(10):813-20. PubMed ID: 17012043
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of concurrent carboplatin during full-dose craniospinal irradiation for high-risk/metastatic medulloblastoma in a resource-limited setting.
Gupta T; Sinha S; Chinnaswamy G; Vora T; Prasad M; Bhat V; Goda JS; Krishnatry R; Chatterjee A; Epari S; Sahay A; Moiyadi A; Shetty P; Patil V; Khatua S; Jalali R; Kurkure P
Pediatr Blood Cancer; 2021 May; 68(5):e28925. PubMed ID: 33533557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
